{"id":"lymecycline","rwe":[{"pmid":"41202498","year":"2025","title":"Unilateral palpebral lupus miliaris disseminatus faciei successfully treated with lymecycline.","finding":"","journal":"Anais brasileiros de dermatologia","studyType":"Clinical Study"},{"pmid":"40787908","year":"2025","title":"Rombus-shaped α-Fe₂O₃ nanoparticles for antibacterial and anticancer applications.","finding":"","journal":"Nanomedicine (London, England)","studyType":"Clinical Study"},{"pmid":"40454079","year":"2025","title":"Molecularly Imprinted Nanoparticle-Based Assay for Tetracycline Determination at Subnanomolar Levels.","finding":"","journal":"ACS omega","studyType":"Clinical Study"},{"pmid":"39541116","year":"2024","title":"First Trimester Tetracycline Exposure and Risk of Major Congenital Malformations.","finding":"","journal":"JAMA network open","studyType":"Clinical Study"},{"pmid":"39474132","year":"2023","title":"In silico drug repurposing using molecular docking and dynamics to target the protein interaction between the SARS-CoV-2 S-glycoprotein and the ACE2 receptor.","finding":"","journal":"F1000Research","studyType":"Clinical Study"}],"tags":[{"label":"lymecycline","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01AA04","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":61.886,"date":"","count":25,"signal":"Drug reaction with eosinophilia and systemic symptoms","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=62)"},{"llr":53.348,"date":"","count":12,"signal":"Hidradenitis","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=53)"},{"llr":40.652,"date":"","count":20,"signal":"Swelling face","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=41)"},{"llr":38.934,"date":"","count":5,"signal":"Serum procollagen type III N-terminal propeptide increased","source":"DrugCentral FAERS","actionTaken":"Reported 5 times (LLR=39)"}],"commonSideEffects":[{"effect":"Drug reaction with eosinophilia and systemic symptoms","drugRate":"LLR 62","severity":"common"},{"effect":"Hidradenitis","drugRate":"LLR 53","severity":"common"},{"effect":"Swelling face","drugRate":"LLR 41","severity":"common"},{"effect":"Serum procollagen type III N-terminal propeptide increased","drugRate":"LLR 39","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"mucomycin","offLabel":[],"synonyms":["lymecycline","mucomycin","ciclolysine","Tetracycline-L-methylenelysine","tetracyclinemethylenelysine"],"timeline":[],"approvals":[],"brandName":"Mucomycin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"lymecycline","explanation":"Think of it like a factory assembly line. Bacteria need to make proteins to function and grow, and Mucomycin blocks the assembly line by binding to the ribosome, which is the part of the cell where proteins are made. This prevents the bacteria from making the proteins they need to survive and multiply.","oneSentence":"Mucomycin works by binding to the bacterial ribosome and inhibiting protein synthesis.","technicalDetail":"Mucomycin binds to the 30S subunit of the bacterial ribosome, specifically to the A site, and inhibits the binding of aminoacyl-tRNA to the ribosome, thereby preventing the addition of new amino acids to the growing peptide chain."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1619","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LYMECYCLINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LYMECYCLINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:11:42.066688","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:39:01.504892+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"demeclocycline","drugSlug":"demeclocycline","fdaApproval":"1960-01-14","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"doxycycline","drugSlug":"doxycycline","fdaApproval":"1967-12-05","patentExpiry":"Dec 19, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"chlortetracycline","drugSlug":"chlortetracycline","fdaApproval":"1950-01-23","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"metacycline","drugSlug":"metacycline","fdaApproval":"","relationship":"same-class"},{"drugName":"oxytetracycline","drugSlug":"oxytetracycline","fdaApproval":"1964-09-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"tetracycline","drugSlug":"tetracycline","fdaApproval":"1953-11-19","genericCount":34,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"minocycline","drugSlug":"minocycline","fdaApproval":"1971-06-30","patentExpiry":"Sep 8, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tigecycline","drugSlug":"tigecycline","fdaApproval":"2005-06-15","patentExpiry":"Oct 8, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"sarecycline","drugSlug":"sarecycline","fdaApproval":"2018-10-01","patentExpiry":"Jan 3, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"omadacycline","drugSlug":"omadacycline","fdaApproval":"2018-10-02","patentExpiry":"Sep 23, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"lymecycline","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"demeclocycline","brandName":"demeclocycline","genericName":"demeclocycline","approvalYear":"1960","relationship":"same-class"},{"drugId":"doxycycline","brandName":"doxycycline","genericName":"doxycycline","approvalYear":"1967","relationship":"same-class"},{"drugId":"chlortetracycline","brandName":"chlortetracycline","genericName":"chlortetracycline","approvalYear":"1950","relationship":"same-class"},{"drugId":"metacycline","brandName":"metacycline","genericName":"metacycline","approvalYear":"","relationship":"same-class"},{"drugId":"oxytetracycline","brandName":"oxytetracycline","genericName":"oxytetracycline","approvalYear":"1964","relationship":"same-class"},{"drugId":"tetracycline","brandName":"tetracycline","genericName":"tetracycline","approvalYear":"1953","relationship":"same-class"},{"drugId":"minocycline","brandName":"minocycline","genericName":"minocycline","approvalYear":"1971","relationship":"same-class"},{"drugId":"tigecycline","brandName":"tigecycline","genericName":"tigecycline","approvalYear":"2005","relationship":"same-class"},{"drugId":"sarecycline","brandName":"sarecycline","genericName":"sarecycline","approvalYear":"2018","relationship":"same-class"},{"drugId":"omadacycline","brandName":"omadacycline","genericName":"omadacycline","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05821478","phase":"PHASE3","title":"Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2025-05-22","conditions":["Hidradenitis Suppurativa"],"enrollment":92,"completionDate":"2028-02-27"},{"nctId":"NCT06447480","phase":"PHASE3","title":"Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-07-01","conditions":["Acne Vulgaris"],"enrollment":420,"completionDate":"2027-09-01"},{"nctId":"NCT01014689","phase":"PHASE3","title":"Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-08","conditions":["Acne Vulgaris"],"enrollment":378,"completionDate":"2010-05"},{"nctId":"NCT01661985","phase":"PHASE4","title":"Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced","status":"UNKNOWN","sponsor":"Ostergotland County Council, Sweden","startDate":"2010-02","conditions":["Urethritis","Cervicitis","Genital Mycoplasma Infection","Chlamydia Trachomatis"],"enrollment":160,"completionDate":"2016-09"},{"nctId":"NCT02149615","phase":"PHASE4","title":"Antiacne Medications Pseudotumor Cerebri","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2014-04","conditions":["Optic Disc Swelling"],"enrollment":310,"completionDate":"2019-12"},{"nctId":"NCT00988026","phase":"PHASE4","title":"Safety and Efficacy Comparison of Minocycline Microgranules Versus Lymecycline in the Treatment of Mild to Moderate Acne","status":"UNKNOWN","sponsor":"Darier","startDate":"2009-06","conditions":["Mild to Moderate Acne"],"enrollment":168,"completionDate":"2010-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000167346","NDDF":"003993","UNII":"7D6EM3S13P","CHEBI":"CHEBI:59040","INN_ID":"1679","RXNORM":"6513","UMLSCUI":"C0024200","ChEMBL_ID":"CHEMBL2103929","KEGG_DRUG":"D06884","DRUGBANK_ID":"DB00256","PUBCHEM_CID":"54707177","SNOMEDCT_US":"387548007","IUPHAR_LIGAND_ID":"10912","MESH_DESCRIPTOR_UI":"D008194"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"99%"},"publicationCount":143,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01AA04","allCodes":["J01AA04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Nov-Dec","pmid":"41202498","title":"Unilateral palpebral lupus miliaris disseminatus faciei successfully treated with lymecycline.","journal":"Anais brasileiros de dermatologia"},{"date":"2025 Oct","pmid":"40787908","title":"Rombus-shaped α-Fe₂O₃ nanoparticles for antibacterial and anticancer applications.","journal":"Nanomedicine (London, England)"},{"date":"2025 May 27","pmid":"40454079","title":"Molecularly Imprinted Nanoparticle-Based Assay for Tetracycline Determination at Subnanomolar Levels.","journal":"ACS omega"},{"date":"2024 Nov 4","pmid":"39541116","title":"First Trimester Tetracycline Exposure and Risk of Major Congenital Malformations.","journal":"JAMA network open"},{"date":"2023","pmid":"39474132","title":"In silico drug repurposing using molecular docking and dynamics to target the protein interaction between the SARS-CoV-2 S-glycoprotein and the ACE2 receptor.","journal":"F1000Research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:39:01.504892+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}